Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 18/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 15/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 13/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5633311 | 0.93 | OPRD1 (0.72) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5629643 | 0.93 | OPRD1 (0.69) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5629405 | 0.93 | OPRD1 (0.80) | OPRD1OPRM1OPRK1CHRM2CHRM3 | |
| SCHEMBL5630841 | 0.92 | OPRD1 (0.68) | OPRD1OPRM1OPRK1 | |
| SCHEMBL6181246 | 0.89 | OPRD1 (0.86) | OPRD1OPRM1OPRK1 | |
| SCHEMBL6604724 | 0.87 | OPRD1 (0.64) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5633214 | 0.87 | OPRD1 (0.64) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5630391 | 0.85 | OPRD1 (0.79) | OPRD1OPRM1OPRK1CHRM2CHRM3 | |
| SCHEMBL5629711 | 0.84 | OPRD1 (0.60) | OPRD1OPRM1OPRK1 | |
| SCHEMBL6612026 | 0.84 | OPRD1 (0.60) | OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186733-B2 | 4-(phenyl-(piperidin-4yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2007-03-06 | — | — | US | claimed |
| US-20040142965-A1 | 4-(phenyl-(piperidin-4yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2004-07-22 | — | — | US | claimed |
| EP-1395556-A1 | 4-(PHENYL-(PIPERIDIN-4-YL)-AMINO)-BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN, ANXIETY OR GASTROINTESTINAL DISORDERS | AstraZeneca AB (SE) | 2004-03-10 | — | — | EP | claimed |
| WO-2002094784-A1 | 4-(PHENYL-(PIPERIDIN-4-YL)-AMINO)-BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN, ANXIETY OR GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2002-11-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142965-A1 | 4-(phenyl-(piperidin-4yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | HTR2C, HTR1D, OPRL1 | OPRD1 4/4885OPRM1 5/4885OPRK1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.